Genetic variants associated with severe cutaneous adverse drug reactions induced by carbamazepine

Abstract

Aims Carbamazepine (CBZ) is one of the most common causative drugs of severe cutaneous adverse drug reactions (SCARs) including Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reactions with eosinophilia and systemic symptoms. Although genetic polymorphisms of the human leucocyte antigens ( HLA ) are well recognized key elements for the susceptibility to CBZ‐induced SCARs, some evidence suggest that polymorphisms of microsomal epoxide hydrolase 1 ( EPHX1 ) may also contribute to the risk of these SCARs. This study investigated the association between the HLA and EPHX1 polymorphisms on CBZ‐induced SCARs in large sample sizes and well‐defined SCARs patients. Methods Ninety‐one CBZ‐induced SCARs Thai patients and 144 CBZ‐tolerant patients were enrolled in the study. The genotypes of HLA‐A , HLA‐B and EPHX1 were determined. Results Only 2 HLA alleles including HLA‐B*15:02 and HLA‐A*24:07 were statistically significant association with CBZ‐induced SJS/TEN. The highest risk was observed in patients with HLA‐B*15:02 allele (OR = 44.33, 95% confidence interval = 20.24–97.09, corrected P ‐value = 6.80 × 10 −29 ). Moreover, HLA‐B75 serotypes were significantly associated with CBZ‐induced SJS/TEN groups with an odds ratio of 81.00 (95% confidence interval = 32.39–202.56, corrected P ‐value = 3.84 × 10 −34 ). There is no association between EPHX1 c.337 T > C polymorphism and all phenotypes of CBZ‐induced SCARs. Conclusion The HLA‐B*15:02 allele is the strongest genetic marker for the prediction of SJS/TEN induced by CBZ in Thai population. Screening for other alleles in the HLA‐B75 serotype increases sensitivity for prediction of a life‐threatening SCARs caused by CBZ.